Trial Outcomes & Findings for Maximizing Outcomes in Treating Acute Migraine (NCT NCT03896009)

NCT ID: NCT03896009

Last Updated: 2023-08-24

Results Overview

Absence of headache pain. AXS-07 vs Placebo.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1594 participants

Primary outcome timeframe

Hour 2 following dose administration

Results posted on

2023-08-24

Participant Flow

Participant milestones

Participant milestones
Measure
AXS-07
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Meloxicam
Taken once upon a qualifying migraine Meloxicam: Meloxicam taken once upon onset of a qualifying migraine.
Rizatriptan
Taken once upon a qualifying migraine Rizatriptan: Rizatriptan taken once upon onset of a qualifying migraine.
Placebo
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Overall Study
STARTED
456
455
456
227
Overall Study
COMPLETED
441
433
434
218
Overall Study
NOT COMPLETED
15
22
22
9

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Maximizing Outcomes in Treating Acute Migraine

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
AXS-07
n=441 Participants
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Meloxicam
n=433 Participants
Taken once upon a qualifying migraine Meloxicam: Meloxicam taken once upon onset of a qualifying migraine.
Rizatriptan
n=434 Participants
Taken once upon a qualifying migraine Rizatriptan: Rizatriptan taken once upon onset of a qualifying migraine.
Placebo
n=218 Participants
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Total
n=1526 Participants
Total of all reporting groups
Age, Continuous
41.1 years
STANDARD_DEVIATION 11.64 • n=5 Participants
41.0 years
STANDARD_DEVIATION 12.13 • n=7 Participants
41.5 years
STANDARD_DEVIATION 10.75 • n=5 Participants
41.0 years
STANDARD_DEVIATION 11.71 • n=4 Participants
41.1 years
STANDARD_DEVIATION 11.54 • n=21 Participants
Sex: Female, Male
Female
357 Participants
n=5 Participants
363 Participants
n=7 Participants
366 Participants
n=5 Participants
185 Participants
n=4 Participants
1271 Participants
n=21 Participants
Sex: Female, Male
Male
84 Participants
n=5 Participants
70 Participants
n=7 Participants
68 Participants
n=5 Participants
33 Participants
n=4 Participants
255 Participants
n=21 Participants
Race (NIH/OMB)
American Indian or Alaska Native
4 Participants
n=5 Participants
1 Participants
n=7 Participants
2 Participants
n=5 Participants
0 Participants
n=4 Participants
7 Participants
n=21 Participants
Race (NIH/OMB)
Asian
9 Participants
n=5 Participants
10 Participants
n=7 Participants
6 Participants
n=5 Participants
4 Participants
n=4 Participants
29 Participants
n=21 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
Race (NIH/OMB)
Black or African American
76 Participants
n=5 Participants
88 Participants
n=7 Participants
84 Participants
n=5 Participants
48 Participants
n=4 Participants
296 Participants
n=21 Participants
Race (NIH/OMB)
White
345 Participants
n=5 Participants
330 Participants
n=7 Participants
332 Participants
n=5 Participants
160 Participants
n=4 Participants
1167 Participants
n=21 Participants
Race (NIH/OMB)
More than one race
3 Participants
n=5 Participants
4 Participants
n=7 Participants
5 Participants
n=5 Participants
4 Participants
n=4 Participants
16 Participants
n=21 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=5 Participants
0 Participants
n=7 Participants
5 Participants
n=5 Participants
2 Participants
n=4 Participants
11 Participants
n=21 Participants

PRIMARY outcome

Timeframe: Hour 2 following dose administration

Population: ITT population consists of all randomized subjects who received study drug and had a qualifying migraine.

Absence of headache pain. AXS-07 vs Placebo.

Outcome measures

Outcome measures
Measure
AXS-07
n=428 Participants
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Placebo
n=209 Participants
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Percentage of Subjects Reporting Headache Pain Freedom
85 Participants
14 Participants

PRIMARY outcome

Timeframe: Hour 2 following dose administration

Population: ITT population consists of all randomized subjects who received study drug and had a qualifying migraine.

Absence of most bothersome symptom, defined at the onset of migraine. AXS-07 vs Placebo.

Outcome measures

Outcome measures
Measure
AXS-07
n=428 Participants
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Placebo
n=209 Participants
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Percentage of Subjects With Absence of Most Bothersome Symptom
158 Participants
51 Participants

Adverse Events

AXS-07

Serious events: 1 serious events
Other events: 49 other events
Deaths: 0 deaths

Meloxicam

Serious events: 0 serious events
Other events: 50 other events
Deaths: 0 deaths

Rizatriptan

Serious events: 0 serious events
Other events: 67 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
AXS-07
n=441 participants at risk
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Meloxicam
n=433 participants at risk
Taken once upon a qualifying migraine Meloxicam: Meloxicam taken once upon onset of a qualifying migraine.
Rizatriptan
n=434 participants at risk
Taken once upon a qualifying migraine Rizatriptan: Rizatriptan taken once upon onset of a qualifying migraine.
Placebo
n=218 participants at risk
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
0.23%
1/441 • Number of events 1 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.00%
0/433 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.00%
0/434 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.00%
0/218 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.

Other adverse events

Other adverse events
Measure
AXS-07
n=441 participants at risk
Taken once upon a qualifying migraine AXS-07 (MoSEIC meloxicam and rizatriptan): AXS-07 taken once upon onset of a qualifying migraine.
Meloxicam
n=433 participants at risk
Taken once upon a qualifying migraine Meloxicam: Meloxicam taken once upon onset of a qualifying migraine.
Rizatriptan
n=434 participants at risk
Taken once upon a qualifying migraine Rizatriptan: Rizatriptan taken once upon onset of a qualifying migraine.
Placebo
n=218 participants at risk
Taken once upon a qualifying migraine Placebo: Placebo taken once upon onset of a qualifying migraine.
Gastrointestinal disorders
Nausea
2.7%
12/441 • Number of events 12 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
3.2%
14/433 • Number of events 15 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
4.8%
21/434 • Number of events 21 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
3.7%
8/218 • Number of events 8 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
Nervous system disorders
Dizziness
1.6%
7/441 • Number of events 7 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
1.2%
5/433 • Number of events 5 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
2.1%
9/434 • Number of events 9 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.92%
2/218 • Number of events 2 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
Nervous system disorders
Somnolence
1.4%
6/441 • Number of events 6 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
2.3%
10/433 • Number of events 10 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
2.1%
9/434 • Number of events 9 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.46%
1/218 • Number of events 1 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
General disorders
All Others, occurring in <1% of Subjects
6.3%
28/441 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
5.1%
22/433 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
7.4%
32/434 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.
0.92%
2/218 • Adverse events were collected after administration of study drug through the final visit (up to 1 week). Any AE was monitored up to a maximum of 30 days after the final visit.
Safety Population includes all subjects who received study drug.

Additional Information

Caroline Streicher, Executive Director, Clinical Operations

Axsome Therapeutics, Inc.

Phone: 212-332-5061

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place